

## **CLAIMS**

1. An anti-Gremlin-1 antibody which comprises heavy chain complementarity determining region (HCDR) sequences contained within a heavy chain variable region (HCVR) of SEQ ID NO: 10 or 12 and/or light chain complementarity determining region (LCDR) sequences contained within a light chain variable region (LCVR) of SEQ ID NO: 11 or 13.
2. An anti-Gremlin-1 antibody which comprises at least one HCDR sequence selected from SEQ ID NOs: 3, 4, 5 and 6 and/or at least one LCDR sequence selected from SEQ ID NOs: 7, 8 and 9.
3. The antibody of claim 2, which comprises a HCDR3 sequence of SEQ ID NO: 6.
4. The antibody of claim 2 or 3, wherein the HCDR1/HCDR2/HCDR3 sequence combination is selected from SEQ ID NOs: 4/5/6 or from SEQ ID NOs: 3/5/6 and/or the LCDR1/LCDR2/LCDR3 sequence combination is selected from SEQ ID NOs: 7/8/9.
5. The antibody of any one of claims 2, 3 or 4, which comprises a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9.
6. The antibody of any one of claims 2-5, which comprises a heavy chain variable region (HCVR) sequence of SEQ ID NO: 10 or 12 and/or a light chain variable region (LCVR) sequence of SEQ ID NO: 11 or 13, or sequences which are at least 95% identical thereto.
7. The antibody of claim 6, which comprises a HCVR and LCVR sequence pair of SEQ ID NOs: 10/11 or 12/13 or sequences which are at least 95% identical thereto.
8. The antibody of claim 7, wherein the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consist of SEQ ID NOs:

4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the HCVR and LCVR comprise at least 95% identity to SEQ ID Nos: 10, 11, 12 and/or 13 respectively.

9. The antibody of any one of claims 6-8, which comprises a heavy chain of SEQ ID NO: 14, 16, 18, 22, 28, 30, 32 or 34 and/or a light chain of SEQ ID NO: 15, 17, 19, 23, 29, 31, 33 or 35, or sequences which are at least 95% identical thereto.

10. The antibody of claim 9, which comprises a heavy and light chain pair of SEQ ID NOs: 14/15, 16/17, 18/19, 22/23, 28/29 or 30/31, 32/33, 34/35, or sequences which are at least 95% identical thereto.

11. The antibody of claim 10, wherein the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consist of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the heavy and light chains comprise at least 95% identity to SEQ ID NOs: 14, 15, 16 and/or 17 respectively.

12. An antibody according to any one of claims 1-11, which is a chimeric, human or humanised antibody.

13. An antibody according to any one of claims 1-12, which is a Fab, modified Fab, Fab', modified Fab', F(ab')<sub>2</sub>, Fv, single domain antibody or an scFv.

14. An isolated polynucleotide encoding an antibody as defined in any one of claims 1-13.

15. An expression vector carrying the polynucleotide of claim 14.

16. A host cell comprising the vector as defined in claim 15.

17. A method of producing the antibody as defined in any one of claims 1-13, comprising culturing the host cell of claim 16 under conditions permitting production of the antibody, and recovering the antibody produced.

18. A pharmaceutical composition comprising an antibody as defined in any one of claims 1-13 and a pharmaceutically acceptable adjuvant and/or carrier.

19. An antibody as defined in any one of claims 1-13 or a pharmaceutical composition as defined in claim 18 for use in a method of treatment of the human or animal body by therapy.

20. The antibody or pharmaceutical composition for use according to claim 19, wherein renal fibrosis such as diabetic nephropathy, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, angiogenesis and/or cancer are treated/prevented.

21. Use of an antibody according to claims 1-13 or a pharmaceutical composition according to claim 18 for the preparation of a medicament for treating or preventing renal fibrosis such as diabetic nephropathy, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, angiogenesis and/or cancer.